Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
03 June 2021 - 10:00PM
Sanofi
launches
€3 million
Planet Mobilization fund
to support employees’
environmental projects
- This year, Sanofi will fund three
employee teams for their environmental programs in Vietnam,
Ireland, France, Belgium and Italy
- In April 2021, Sanofi expanded its
social commitments, including its global environmental
sustainability program, Planet Mobilization
PARIS
– June 3, 2021 –
As part of a long-standing commitment to reduce the environmental
footprint of the company’s products and activities, Sanofi launched
a €3 million Planet Mobilization fund to support employee ideas and
projects that will further contribute to a healthier environment.
This year, three Sanofi teams will have their projects funded.
For several years, Sanofi has been implementing
a global environmental roadmap, Planet Mobilization, which is
embedded in Sanofi’s long-term strategy. The program covers all
Sanofi activities and sites and the entire lifecycle of products,
from raw materials used in production all the way to their
disposal.
“Because the fight against climate change is
also a fight for the health and well-being, Sanofi commits to
Planet Mobilization” says Philippe Luscan, Executive Vice
President, Global Industrial Affairs. “We strongly believe our
employees are the most powerful agents of positive change for
people, and for the planet. It’s with this ambition and objectives
in mind that we decided to create a fund of €3 million to finance
ideas and projects coming from our employees in support of our
environmental ambition. Today, it is fair to say that teams all
over the world took up the challenge, even beyond our expectations.
That’s collective intelligence in motion.”
An
Entrepreneurial Program
to Support Employee IdeasThis
year, more than 500 employees from 63 sites in 29 countries
participated in the company’s environmental sustainability ideation
program. A full program of bootcamps, hack-a-thons, and design
thinking workshops led by Sanofi’s Innovation Lab helped the teams
turn their ideas into sustainable projects.
Three winning projects were selected this
inaugural year. The projects will be implemented and financed by
Sanofi’s Planet Mobilization fund:
- Vietnam: “Rice is
the New
Green” is a project from Sanofi’s
Hô Chi Minh team to implement the first green and circular
large-scale rice husk biomass. Rice husk is a byproduct of paddy
processing in the rice mills and can provide a convenient and
environmentally sustainable, convenient source of dry biomass
energy. This will allow Sanofi’s Hô Chi Minh site to become
a fossil fuel free site, eliminating 2.3 thousand tons
of carbon dioxide a year and reduce steam costs by 40%.
- Europe: “IDRA” is
a project from three country sites in Europe, including Anagni,
Italy; Compiègne, France; and Geel, Belgium. The project aims at
recycling treated wastewater from the sites to be directly reused
on site. The three pilot plants could save up to 220 million
liters of water per year. This is the equivalent of filling nearly
70 Olympic pools.
- Ireland: “Waterford Loves
Planet Not Plastic” is an education project to help reduce
plastic waste. Through information via school programs, nature
restoration programs such as coastal clean-ups, and an app
measuring plastic waste and incentivizing reduced consumption,
Sanofi Ireland 'ambassadors' will contribute to their communities
more balanced use of plastic and the management of its waste.
Sanofi Aims for Carbon
NeutralitySanofi has committed to reduce its greenhouse
gas emissions by 55% by 2030 in line with limiting global warming
to 1.5°C and is aiming for carbon neutrality by 2050. The new
carbon reduction objectives are validated by the Science Based
Target initiative, a partnership between Carbon Disclosure Project,
the United Nations Global Compact, World Resources Institute, and
WWF.
To that order and to minimize the potential
direct and indirect impacts of its business on the environment
throughout the whole lifecycle of its products, the company intends
to:
- protect ecosystems by introducing
biodiversity protection plans at all its sites located near
sensitive areas by 2025;
- implement water stewardship and
water efficiency plans on 100% of its manufacturing sites by
2030;
- foster eco-design for all its new
products and packaging by 2025 and for its top-selling
products by 2030, and remove all pre-formed plastic packaging
(blister packs) for its vaccines by 2027;
- reduce, recycle, and recover more
than 90% of its waste by 2025;
- use 100% renewable electricity
across its operations and target a carbon-neutral car fleet, both
by 2030; and
- prevent any impact of its medicines on the environment across
100% of its manufacturing sites by 2025.
Sanofi also supports and works with its
suppliers all over the world to reduce their greenhouse gas
emissions and environmental impact to create more sustainable
sourcing of raw materials.
To date, the company has already notably:
- reduced GHG emission from its
activities by 27% since 2015;
- designed a new entirely recyclable
cardboard packaging for vaccines, which replaces aluminum and PVC
blisters;
- reused, recycled, or recovered 73%
of its waste; and
- reduced by 22% its water withdrawal
from 2015 to 2020.
More on Sanofi’s environmental management and achievements:
https://www.sanofi.com/en/our-responsibility/environmental-sustainability
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Media Relations ContactsAshleigh
Koss Tel: +1 (908) 981-8745Ashleigh.Koss@sanofi.com Sandrine
GuendoulTel.: +33 (0)6 25 09 14
25sandrine.guendoul@sanofi.com |
Investor Relations Contacts ParisEva
Schaefer-JansenArnaud DelepineNathalie Pham Investor
Relations Contacts North AmericaFelix LauscherFara
BerkowitzSuzanne Greco IR main line:Tel.: +33 (0)1 53 77 45
45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact |
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024